DIA: Driving Insights to Action
Science:Life Sciences
In March 2019, the Health Ministry of India released new guidelines for clinical research. What is the state of pre-market and post-market safety for patients and drugs in India, six months after these new guidelines were announced? Dr. Srikanth Krishnamurthy, a consulting pulmonologist at Sri Bala Medical Centre and Hospital, discusses the pre-market clinical research safety perspective; and Dr. J. Vijay Venkatraman, Managing Director and CEO at Oviya MedSafe, contributes the perspective of post-market drug safety in India.
DIA 2018 Co-Chair: Patient Activists Are “Our Best Friends”
Need for Value Creates Opportunity for Patients
Can Europe Optimize Healthcare Quality AND Pricing?
Rules for Successful Patient-Industry Engagement
Multiple Channels Can Share “One Medical Voice”
Advertising & Promotion: What You Can (and Can’t) Say
Could Precision Medicine Deliver “You on a Chip”?
“Enlightened Regulation” Illuminating Translational Science
Time and Place for Innovation in a Pandemic Outbreak?
SFDA Talks Drug Pricing & Shortages in Advance of MERC 2017
Translating Medical Information into Effective Communication
Tufts eClinical Study: Complexity Overrunning Technology
Post-Brexit PV in Europe “An Issue We Shouldn’t Underestimate”
CDER Director: Interest in How Patients Feel & Function
EU Clinical Trial Regulation Streamlines to "Matter of One"
The Gaps In Drug Pricing
Biosimilars’ Good News for Patients
Pace of Innovation vs. Regulation: Combination Challenge
Oligonucleotides Driving Personalized Medicine Research
Celebrating 150 Years with Better Care for Canadians
Create your
podcast in
minutes
It is Free
DNA Today: A Genetics Podcast
Short Wave
Unexplainable
COMPLEXITY
Stuff To Blow Your Mind